Related Experiment Video
Updated: Jul 30, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer
Kalevi Kairemo1,2, Marina Hodolic3
1Department of Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, 00180 Helsinki, Finland.
Abstract:
Prostate cancer is dependent on the action of steroid hormones on the receptors. Endocrine therapy inhibits hormone production or blocks the receptors, thus providing clinical benefit to many, but not all, oncological patients. It is difficult to predict which patient will benefit from endocrine therapy and which will not. Positron Emission Tomography (PET) imaging of androgen receptors (AR) may provide functional information on the likelihood of endocrine therapy response in individual patients. In this article, we review the utility of [18F]FDHT-PET imaging in prostate, breast, and other hormone-dependent cancers expressing AR. The methodologies, development, and new possibilities are discussed as well.
Insights
Positron Emission Tomography (PET) imaging of androgen receptors (AR) may predict response to endocrine therapy in hormone-dependent cancers. This review explores [18F]FDHT-PET
Area of Science:
- Oncology
- Nuclear Medicine
- Endocrinology
Background:
- Prostate cancer relies on steroid hormones and androgen receptors (AR) for growth.
- Endocrine therapy is a common treatment but patient response is variable.
- Predicting treatment efficacy remains a clinical challenge.
Purpose of the Study:
- To review the utility of [18F]FDHT-PET imaging for assessing androgen receptor (AR) status.
- To evaluate the potential of [18F]FDHT-PET in predicting endocrine therapy response.
- To discuss methodologies, development, and future applications of AR-PET imaging.
Main Methods:
- Review of existing literature on [18F]FDHT-PET imaging.
- Focus on applications in prostate, breast, and other AR-expressing cancers.
- Discussion of imaging protocols and data interpretation.
Main Results:
- [18F]FDHT-PET offers functional imaging of AR.
- PET imaging may provide insights into endocrine therapy response likelihood.
- Potential for personalized treatment strategies in hormone-dependent cancers.
Conclusions:
- [18F]FDHT-PET imaging shows promise for predicting endocrine therapy outcomes.
- This technique could improve patient selection for hormonal treatments.
- Further research is needed to fully establish its clinical role.
